



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackson
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek
Marsha A. Rose

Young Tang
Christopher J. Walsh
W. Blake Coblenz*
James J. Pohl*
John T. Haran*
Mark W. Rygiel
Kevin W. McCabe

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

June 12, 2006

WRITER'S DIRECT NUMBER:

(202) 772-8764

INTERNET ADDRESS:

CWALSH@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1618

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/514,427; § 371 Date: November 16, 2004
For: **Substituted 4-Aryl-4H-pyrrolo[2,3-h]chromenes and Analogs as
Activators of Caspases and Inducers of Apoptosis and the Use
Thereof**

Inventors: Cai *et al.*
Our Ref: 1735.0770001/RWE/CJW

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (3 sheets);
3. Form PTO/SB/08B (8 sheets);
4. Copies of eighty-seven (87) references (Documents FP1-FP18 and NPL1-NPL69);
and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
June 12, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Christopher J. Walsh". The signature is fluid and cursive, with the first name "Christopher" and last name "Walsh" clearly distinguishable.

Christopher J. Walsh
Attorney for Applicants
Registration No. 55,709

CJW/dab
543526_1.DOC
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cai *et al.*

Appl. No.: 10/514,427

§ 371 Filing Date: November 16, 2004

For: **Substituted 4-Aryl-4H-pyrrolo[2,3-*h*]chromenes and
Analogues as Activators of Caspases
and Inducers of Apoptosis And the
Use Thereof**

Confirmation No.: 4080

Art Unit: 1618

Examiner: Fay, Zohreh A.

Atty. Docket: 1735.0770001/RWE/CJW

**Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1-FP18** and **NPL1-NPL69** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1-US35**, cited on the attached Forms PTO/SB/08A are not submitted.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications and to the prosecution histories of related U.S. Patents and U.S. Patent Application Publications, which are directed to related technical subject matter:

U.S. Application No. 09/705,840, inventors Drewe, J.A., *et al.*, filed November 6, 2000, now patented as 6,906,203 B1, cited herein as document **US28**, and its prosecution history, cited herein as document **NPL68**;

U.S. Application No. 10/146,138, inventors Cai, S.X., *et al.*, filed May 16, 2002, now published as 2003/0065018 A1, cited herein as document **US30**, and its prosecution history, cited herein as document **NPL65**;

U.S. Application No. 10/146,136, inventors Cai, S.X., *et al.*, filed May 16, 2002, now patented as U.S. Patent No. 7,015,328, cited herein as document **US29**, and its prosecution history, cited herein as document **NPL67**;

U.S. Application No. 10/989,057, inventors Cai, S.X., *et al.*, filed November 16, 2004, now published as 2005/0090526 A1, cited herein as document **US31**, and a related Office Action, cited herein as document **NPL69**;

U.S. Application No. 11/072,499, inventors Drewe, J.A., *et al.*, filed March 7, 2005, now published as 2005/0154015 A1, cited herein as document **US32**;

U.S. Application No. 10/146,139, inventors Cai, S.X., *et al.*, filed May 16, 2002, now patented as 6,858,607 B1, cited herein as document **US26**, and its prosecution history, cited herein as document **NPL66**;

U.S. Application No. 10/514,426, inventors Cai, S.X., *et al.*, filed November 16, 2004, now published as 2005/0176750 A1, cited herein as document **US34**;

U.S. Application No. 11/150,586, inventors Cai, S.X., *et al.*, filed June 13, 2005, now published as 2006/0035925 A1, cited herein as document **US35**; and

U.S. Application No. 10/477,953, inventors Cai, S.X., *et al.*, filed November 18, 2003, now published as 2005/0165053, cited herein as document **US33**.

The identification of these U.S. Patent Applications and any corresponding prosecutions is not to be construed as a waiver of secrecy as to these applications now or

upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Forms PTO/SB/08A and PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Christopher J. Walsh". The signature is fluid and cursive, with the first name "Christopher" and last name "Walsh" clearly distinguishable.

Christopher J. Walsh
Attorney for Applicants
Registration No. 55,709

Date: June 12, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

536299_1.DOC

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				§ 371 Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	1	of	3	Attorney Docket Number	1735.0770001/RWE/CJW

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	US1	4,303,656	12/01/1981	Sime <i>et al.</i>	
	US2	4,698,345	10/06/1987	Dicker <i>et al.</i>	
	US3	5,281,619	01/25/1994	Dell <i>et al.</i>	
	US4	5,284,868	02/08/1994	Dell <i>et al.</i>	
	US5	5,434,160	07/18/1995	Dell <i>et al.</i>	
	US6	5,514,706	05/07/1996	Ambler <i>et al.</i>	
	US7	5,571,818	11/05/1996	Williams, A.C.	
	US8	5,574,034	11/12/1996	Williams, A.C.	
	US9	5,576,325	11/19/1996	Williams, A.C.	
	US10	5,624,953	04/29/1997	Ambler <i>et al.</i>	
	US11	5,637,589	06/10/1997	Lee <i>et al.</i>	
	US12	5,726,204	03/10/1998	Lee <i>et al.</i>	
	US13	5,741,818	04/21/1998	Dimmock, J.R.	
	US14	5,847,165	12/08/1998	Lee <i>et al.</i>	
	US15	5,902,792	05/11/1999	Jayaram, H.N.	
	US16	5,994,390	11/30/1999	Jacobsen <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	EP 0 481 243 A1	04/22/1992	Takeda Chemical Industries, Ltd.		
	FP2	EP 0 537 949 A1	04/21/1993	Lilly Industries Limited		
	FP3	EP 0 599 514 A2	06/01/1994	Lilly Industries Limited		
	FP4	EP 0 619 314 A1	10/12/1994	Eli Lilly and Company		
	FP5	EP 0 618 206 B1	09/17/1997	Lilly Industries Limited		
	FP6	WO 96/20721 A1	07/11/1996	The General Hospital Corporation		
	FP7	WO 98/24427 A2	06/11/1998	Angiotech Pharmaceuticals, Inc.		
	FP8	WO 99/18856 A1	04/22/1999	Cytovia, Inc.		
	FP9	WO 99/54286 A2	10/28/1999	Wayne Hughes Institute		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/514,427
				§ 371 Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	2	of	3	Attorney Docket Number	1735.0770001/RWE/CJW

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US17	6,160,010	12/12/2000	Uckun <i>et al.</i>	
	US18	6,221,900 B1	04/24/2001	Uckun <i>et al.</i>	
	US19	6,258,824 B1	07/10/2001	Yang, B.V.	
	US20	6,294,575 B1	09/25/2001	Uckun <i>et al.</i>	
	US21	6,303,652 B1	10/16/2001	Uckun <i>et al.</i>	
	US22	6,323,228 B1	11/27/2001	BaMaung <i>et al.</i>	
	US23	6,365,626 B1	04/02/2002	Uckun <i>et al.</i>	
	US24	6,388,092 B2	05/14/2002	Yang, B.V.	
	US25	6,828,091 B2	12/07/2004	Kasibhatla <i>et al.</i>	
	US26	6,858,607 B1	02/22/2005	Cai <i>et al.</i>	
	US27	6,858,609 B2	02/22/2005	Janssen <i>et al.</i>	
	US28	6,906,203 B1	06/14/2005	Drewe <i>et al.</i>	
	US29	7,015,328 B2	03/21/2006	Cai <i>et al.</i>	
	US30	2003/0065018 A1	04/03/2003	Cai <i>et al.</i>	
	US31	2005/0090526 A1	04/28/2005	Cai <i>et al.</i>	
	US32	2005/0154015 A1	07/14/2005	Drewe <i>et al.</i>	
	US33	2005/0165053 A1	07/28/2005	Cai <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP10	WO 99/62510 A2	12/09/1999	Angiotech Pharmaceuticals, Inc.		
	FP11	WO 00/04901 A1	02/03/2000	Thomas Jefferson University		
	FP12	WO 00/47574 A1	08/17/2000	Pfizer Products Inc.		
	FP13	WO 01/34591 A2	05/17/2001	Cytovia, Inc.		
	FP14	WO 02/092076 A1	11/21/2002	Cytovia, Inc. and Shire BioChem, Inc.		
	FP15	WO 02/092083 A1	11/21/2002	Cytovia, Inc.		
	FP16	WO 02/092594 A1	11/21/2002	Cytovia, Inc.		
	FP17	WO 03/096982 A2	11/27/2003	Cytovia, Inc. and Shire BioChem, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	1	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Abstract of Elgamal, M.H.A., <i>et al.</i> , "Synthesis of some novel nitrogenous furocoumarin derivatives," <i>Polish J. Chem.</i> 72:735-745, Polish Chemical Society (1998), Accession No. 128:321530 CA	
	NPL2	Abstract of El-Taweel, M.A.E.A., <i>et al.</i> , "Synthesis of 4H-naphtho[2,1-b]pyrans, benzo [h] coumarins, 4H-naphtho[2,1-b:6.5-b]dipyrans 4H-naphtho[1,2-b:3,4-b'] dipyrans and pyridine derivatives," <i>Anales de Quimica</i> 91:589-593, Real Sociedad Espanola de Quimica (1995), Accession No. 125:114568 CA	
	NPL3	Abstract of European Patent No. EP 0 481 243, Meguro, K. <i>et al.</i> , "Tricyclic heterocyclic compounds, their production and use," Accession No. 117:69733 CA	
	NPL4	Abstract of Radwan, A.M., <i>et al.</i> , "A new route for the synthesis of 1,2,4-triazole and 3,4-disubstituted cinnoline derivatives," <i>J. Chem. Soc. Pakistan</i> 17:113-117, Chemical Society of Pakistan (1995), Accession No. 124:117193 CA	
	NPL5	Abstract of Tawada, H., <i>et al.</i> , "Synthesis of 3-ureido derivatives of coumarin and 2-quinolone as potent acyl-CoA: cholesterol acyltransferase inhibitors," <i>Chem. Pharm. Bull.</i> 43:616-625, Pharmaceutical Society of Japan (1995), Accession No. 123:339669 CA	
	NPL6	Abstract of Woods, L.L. and Sterling, J., "New synthesis of naphtho[1,2-b]pyran-2-ones," <i>J. Org. Chem.</i> 29:502-504, American Chemical Society (1964), Accession No. 60:44584 CA	
	NPL7	Abstract of Al-Mousawa, S.M., <i>et al.</i> , "Synthesis of New Condensed 2-Amino-4H-pyran-3-carbonitriles and of 2-Aminoquinoline-3-carbonitriles," <i>Organic Preparations and Procedures Int.</i> 31:305-313, Organic Preparations and Procedures, Inc. (1999), CAPLUS Accession No. 131:199593, 2 pages (1999)	
	NPL8	Al-Mousawi, S.M., <i>et al.</i> , "Synthesis of New Condensed 2-Amino-4H-pyran-3-carbonitriles and of 2-Aminoquinoline-3-carbonitriles," <i>Organic Preparations and Procedures Int.</i> 31:305-313, Organic Preparations and Procedures, Inc. (1999)	
	NPL9	<i>Apoptosis and Cancer Chemotherapy</i> , Hickman, J.A. and Dive, C., eds., Humana Press, Totowa, NJ (1999), 4 pages (includes Title Page, Foreword, Preface, Contents and Contributors)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	2	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
	NPL10	Batteux, F., <i>et al.</i> , "Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand," <i>J. Immunol.</i> 162:603-608, The American Association of Immunologists (1999)		
	NPL11	Birch, K.A., <i>et al.</i> , "LY290181, an Inhibitor of Diabetes-Induced Vascular Dysfunction, Blocks Protein Kinase C-Stimulated Transcriptional Activation Through Inhibition of Transcription Factor Binding to a Phorbol Response Element," <i>Diabetes</i> 45:642-650, The American Diabetes Association (1996)		
	NPL12	Bloxham, J., <i>et al.</i> , "Preparation of Some New Benzylidenemalononitriles by an S _N Ar Reaction: Application to Naphtho[1,2- <i>b</i>]pyran Synthesis," <i>Heterocycles</i> 38:399-408, The Japanese Institute of Heterocyclic Chemistry (1994)		
	NPL13	Boirivant, M., <i>et al.</i> , "Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis," <i>Gastroenterol.</i> 116:557-565, Elsevier, Inc. (1999)		
	NPL14	Bremner, A.R.F. and Beattie, R.M., "Therapy of Crohn's disease in childhood," <i>Expert Opin. Pharmacother.</i> 3:809-825, Ashley Publications Ltd. (2002)		
	NPL15	Chandrasekhar, S., <i>et al.</i> , "Identification of a Novel Chemical Series That Blocks Interleukin-1-Stimulated Metalloprotease Activity in Chondrocytes," <i>J. Pharmacol. Exper. Ther.</i> 273:1519-1528, The American Society for Pharmacology and Experimental Therapeutics (1995)		
	NPL16	Coven, T.R., <i>et al.</i> , "PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis," <i>Photoderm. Photoimmunol. Photomed.</i> 15:22-27, Munksgaard (1999)		
	NPL17	Elagamey, A.G.A., <i>et al.</i> , "Nitriles In Heterocyclic Synthesis: Novel Syntheses of Benzo[<i>b</i>]pyrans, Naphtho[1,2- <i>b</i>]pyrans, Naphtho[2,1- <i>b</i>]pyrans, Pyrano[3,2- <i>h</i>]quinolines and Pyrano[3,2- <i>c</i>]quinolines," <i>Collection Czechoslovak Chem. Commun.</i> 53:1534-1538, Czechoslovak Academy of Sciences (1988)		
	NPL18	Elagamey, A.G.A. and El-Taweel, F.M.A.A., "Nitriles in heterocyclic synthesis: Synthesis of condensed pyrans," <i>Indian J. Chem.</i> 29B:885-886, The Council of Scientific & Industrial Research, New Delhi (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
Examiner Name	Fay, Zohreh A.				
Sheet	3	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL19	Elgert, K.D., "Immunology - Understanding the Immune System," pp. 315-331, John Wiley & Sons, Inc. (1996)	
	NPL20	Ellis, R.E., <i>et al.</i> , "Mechanisms and Functions of Cell Death," <i>Ann. Rev. Cell Biol.</i> 7:663-698, Annual Reviews, Inc. (1991)	
	NPL21	Friesen, C., <i>et al.</i> , "Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells," <i>Nat. Med.</i> 2:574-577, Nature Publishing Co. (1996)	
	NPL22	Gourdeau, H., <i>et al.</i> , "Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents," <i>Mol. Cancer Ther.</i> 3:1375-1383, American Association for Cancer Research (November 2004)	
	NPL23	Greenwald, R.B., <i>et al.</i> , "Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds," <i>J. Med. Chem.</i> 42:3657-3667, American Chemical Society (1999)	
	NPL24	Heenen, M., <i>et al.</i> , "Methotrexate induces apoptotic cell death in human keratinocytes," <i>Arch. Dermatol. Res.</i> 290:240-245, Springer-Verlag (1998)	
	NPL25	Infante, A.J., <i>et al.</i> , "The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis," <i>J. Pediatr.</i> 133:629-633, Mosby, Inc. (1998)	
	NPL26	Kasibhatla, S., <i>et al.</i> , "Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity," <i>Mol. Cancer Ther.</i> 3:1365-1373, American Association for Cancer Research (November 2004)	
	NPL27	Kemnitzner, W., <i>et al.</i> , "Discovery of 4-Aryl-4H-chromenes as a New Series of Apoptosis Inducers Using a Cell- and Caspase-based High-Throughput Screening Assay. 1. Structure-Activity Relationships of the 4-Aryl Group," <i>J. Med. Chem.</i> 47: 6299-6310, American Chemical Society (November 2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	4	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL28	Kemnitzner, W. <i>et al.</i> , "Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions," <i>Bioorg. Med. Chem. Letts.</i> 15:4745-4751, Elsevier Ltd. (September 2005)	
	NPL29	Klokol, G.V., <i>et al.</i> , "Cyclization of Nitriles. XXIII. Addition of Active Phenols to Electron-Deficient Ethylenes, Accompanied by Cyclization to 2-Amino-4H-benzo[b]pyrans. Crystal Structure of 2-Amino-4-(2-fluorophenyl)-3-ethoxycarbonyl-4H-naphtho[2,1-b]pyran," <i>J. Organic Chem. of USSR</i> 23:369-377, Plenum Publishing Corporation (1987)	
	NPL30	Klokol, G.V., <i>et al.</i> , "Cyclization of nitriles. XXIII. Addition of active phenols to electron-deficient ethylenes with cyclization to 2-amino-4H-benzo[b]pyrans. Crystal structure of 2-amino-4-(2-fluorophenyl)-3-(ethoxycarbonyl)4H-naphtho[2,1-b]pyran," <i>Chem. Abstr.</i> 108:5822c, Chemical Abstracts Service (1988)	
	NPL31	Leu, Y.-L., <i>et al.</i> , "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)," <i>J. Med. Chem.</i> 42:3623-3628, American Chemical Society (1999)	
	NPL32	López-Hoyos, M., <i>et al.</i> , "Regulation of B cell apoptosis by Bcl-2 and Bcl-X _L and its role in the development of autoimmune diseases (Review)," <i>Intl. J. Mol. Med.</i> 1:475-483, D.A. Spandidos (1998)	
	NPL33	Los, M., <i>et al.</i> , "Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases)," <i>Blood</i> 90:3118-3129, W.B. Saunders Company (1997)	
	NPL34	Ohsako, S. and Elkon, K.B., "Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis," <i>Cell Death Diff.</i> 6:13-21, Stockton Press (1999)	
	NPL35	O'Reilly, L.A. and Strasser, A., "Apoptosis and autoimmune disease," <i>Inflamm. Res.</i> 48:5-21, Birkhäuser Verlag, Basel (1999)	
	NPL36	Orrenius, S., "Apoptosis: molecular mechanisms and implications for human disease," <i>J. Internal Med.</i> 237:529-536, Blackwell Science Ltd. (1995)	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	5	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL37	Ozawa, M., <i>et al.</i> , "312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions," <i>J. Exp. Med.</i> 189:711-718, The Rockefeller University Press (1999)	
	NPL38	Panda, D., <i>et al.</i> , "Suppression of Microtubule Dynamics by LY290181," <i>J. Biol. Chem.</i> 272:7681-7687, The American Society for Biochemistry and Molecular Biology, Inc. (1997)	
	NPL39	Paull, K.D., <i>et al.</i> , "Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-assisted Evaluation of Differential Cytotoxicity Data," <i>Can. Res.</i> 52:3892-3900, The American Association for Cancer Research, Inc. (1992)	
	NPL40	Radwan, S.M., <i>et al.</i> , "Synthesis and Some Reactions of New Benzo[b]pyran Derivatives," <i>Phosphorus, Sulfur, and Silicon</i> 101:207-211, Overseas Publishers Association (1995)	
	NPL41	Ram, V.J. and Verma, M., "Synthesis of 4H-benzopyrans, benzopyrano[2,3-d]pyrimidines and related compounds as biodynamic agents," <i>Ind. J. Chem.</i> 33B:908-911, Publications & Information Directorate (CSIR) (1994)	
	NPL42	Robinson, M., "Medical Therapy of Inflammatory Bowel Disease for the 21 st Century," <i>Eur. J. Surg.</i> 164(Suppl. 582):90-98, Scandinavian University Press (1998)	
	NPL43	Savill, J., "Apoptosis in resolution of inflammation," <i>J. Leukoc. Biol.</i> 61:375-380, Society for Leukocyte Biology (1997)	
	NPL44	Schmitt, E., <i>et al.</i> , "The Bcl-xL and Bax- α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation," <i>Biochem. Cell Biol.</i> 75:301-314, National Research Council of Canada (1997)	
	NPL45	Sen, S. and D'Incalci, M., "Apoptosis: Biochemical events and relevance to cancer chemotherapy," <i>FEBS</i> 307:122-127, Elsevier Science Publishers B.V. (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
Examiner Name	Fay, Zohreh A.				
Sheet	6	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL46	Sharanin, Y.A. and Klokot, G.V., "Synthesis of 2-amino-4H-chromenes," <i>Chem. Abstr.</i> 99:212393z, Chemical Abstracts Service (1983)	
	NPL47	Sharanin, Y.A. and Klokot, G.V., "Synthesis of 2-Amino-4H-chromenes," <i>J. Organic Chem. of USSR</i> 19:1582-1583, Plenum Publishing Corporation (1984)	
	NPL48	Shevach, E.M., "Animal Models for Autoimmune and Inflammatory Disease," <i>Current Protocols in Immunology, Suppl.</i> 52:15.0.1-15.0.6, John Wiley & Sons, Inc. (2002)	
	NPL49	Simone, J.V., "Oncology: Introduction," <i>Cecil Textbook of Medicine</i> , 20 th Edition, Bennett, J.C. and Plum, F., eds., vol. 1, pp. 1004-1010, W.B. Saunders Company (1996)	
	NPL50	Singh, B., <i>et al.</i> , "Immune therapy in inflammatory bowel disease and models of colitis," <i>Brit. J. Surg.</i> 88:1558-1569, Blackwell Science Ltd. (2001)	
	NPL51	Smith, C.W., <i>et al.</i> , "The Anti-Rheumatic Potential of a Series of 2,4-Di-substituted-4H-naphtho[1,2-b]pyran-3-carbonitriles," <i>Biorg. Med. Chem. Lett.</i> 5:2783-2788, Elsevier Science Ltd. (1995)	
	NPL52	Supplementary Partial European Search Report for European Patent Application No. 02741704.7, European Patent Office, The Hague, Netherlands, 6 pages, dated August 30, 2005	
	NPL53	Thornberry, N.A., <i>et al.</i> , "A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B," <i>J. Biol. Chem.</i> 272:17907-17911, The American Society for Biochemistry and Molecular Biology, Inc. (1997)	
	NPL54	Thornberry, N.A., "Caspases: key mediators of apoptosis," <i>Chem. Biol.</i> 5:R97-R103, Current Biology Ltd. (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	7	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL55	Thornberry, N.A., "The caspase family of cysteine proteases," <i>Brit. Med. Bull.</i> 53:478-490, Oxford University Press (1997)	
	NPL56	Vaishnaw, A.K., <i>et al.</i> , "The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations," <i>J. Clin. Invest.</i> 103:355-363, American Society for Clinical Investigation (1999)	
	NPL57	Wachlin, G., <i>et al.</i> , "IL-1 β , IFN- γ and TNF- α increase vulnerability of pancreatic beta cells to autoimmune destruction," <i>J. Autoimmunity</i> 20:303-312, Elsevier Science Ltd. (June 2003)	
	NPL58	Wakisaka, S., <i>et al.</i> , "Modulation of proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)," <i>Clin. Exp. Immunol.</i> 114:119-128, Blackwell Science (1998)	
	NPL59	Wiernicki, T.R., <i>et al.</i> , "Inhibition of Vascular Smooth Muscle Cell Proliferation and Arterial Intimal Thickening by a Novel Antiproliferative Naphthopyran," <i>J. Pharmacol. Exper. Ther.</i> 278:1452-1459, The American Society for Pharmacology and Experimental Therapeutics (1996)	
	NPL60	Wood, D.L., <i>et al.</i> , "Inhibition of Mitosis and Microtubule Function through Direct Tubulin Binding by a Novel Antiproliferative Naphthopyran LY290181," <i>Mol. Pharmacol.</i> 52:437-444, Williams & Wilkins (1997)	
	NPL61	Wyllie, A.H., "Cell death: a new classification separating apoptosis from necrosis," in <i>Cell death in biology and pathology</i> , Bowen, I.D. and Lockshin, R.A., eds., Chapman and Hall, London, pp. 9-34 (1981)	
	NPL62	Wyllie, A.H., <i>et al.</i> , "Cell Death: The Significance of Apoptosis," <i>Int. Rev. Cyt.</i> 68:251-306, Academic Press, Inc. (1980)	
	NPL63	Zhou, T., <i>et al.</i> , "Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases," <i>Nature Med.</i> 5:42-48, Nature Publishing Group (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/514,427
				Filing Date	November 16, 2004
				First Named Inventor	CAI, Sui Xiong
				Art Unit	1626
				Examiner Name	Fay, Zohreh A.
Sheet	8	of	8	Attorney Docket Number	1735.0770001/RWE/CJW

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL64	International Search Report for International Application No. PCT/US03/15427, United States Patent Office, Alexandria, Virginia, mailed on June 30, 2004	
	NPL65	Prosecution history for Cai, S.X. <i>et al.</i> , U.S. Application No. 10/146,138, filed May 16, 2002, now published as 2003/0065018 A1	
	NPL66	Prosecution history for Cai, S.X. <i>et al.</i> , U.S. Application No. 10/146,139, filed May 16, 2002, now patented as 6,858,607 B1	
	NPL67	Prosecution history for Cai, S.X. <i>et al.</i> , U.S. Application No. 10/146,136, filed May 16, 2002, now published as 2003/0114485 A1	
	NPL68	Prosecution history for Drewe, J.A. <i>et al.</i> , U.S. Application No. 09/705,840, filed November 6, 2000, now patented as 6,906,203 B1	
	NPL69	Copy of Office Action for U.S. Application No. 10/989,057, Cai, S.X., <i>et al.</i> , filed November 16, 2004, mailed March 16, 2006	

536291_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.